Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2013 Oct 23;20(1):10.1016/j.bbmt.2013.10.018. doi: 10.1016/j.bbmt.2013.10.018

Table 2.

Post HCT outcomes: univariate analysis (Study population n=233)

Outcomes N Eval Prob (95% CI)
Neutrophil engraftment 232
 28-day 84 (78–88)%
 100-day 97 (92–99)%
Platelet recovery 215
 28-day 47 (40–53)%
 100-day 77 (70–82)%
Grade 2–4 acute GVHD 232
 100-day 37 (30–43)%
Grade 3–4 acute GVHD 232
 100-day 19 (15–25)%
Chronic GVHD 224
 1-year 42 (35–48)%
 3-year 50 (43–57)%
 5-year 51 (44–58)%
Relapse/progression 218
 1-year 43 (36–49)%
 3-year 47 (40–53)%
 5-year 48 (42–55)%
Non-relapse mortality 218
 1-year 18 (13–23)%
 3-year 22 (16–27)%
 5-year 24 (18–31)%
Progression-free survival 218
 1-year 39 (33–46)%
 3-year 32 (26–38)%
 5-year 27 (21–34)%
Overall survival 233
 1-year 62 (55–68)%
 3-year 52 (45–58)%
 5-year 47 (40–53)%